Navigation Links
The Shift from Treatment to Prevention: A Drive towards Cutting Healthcare Costs
Date:1/23/2013

MOUNTAIN VIEW, Calif., Jan. 23, 2013 /PRNewswire/ -- Many healthcare experts believe exigent healthcare costs are controllable by focusing on the pre-emptive component of healthcare.  Following this trend, a lot of emphasis was recently put on providing adequate preventative care, which provides immense opportunities for both healthcare and non-healthcare organizations.  Within the preventative care space, the products and services can be segmented into three primary components:  patient education systems (including wellness programs), aging in place services, and remote monitoring devices.

New analysis from Frost & Sullivan's (http://medtech.frost.com) Shifting Toward Preventative Healthcare Models in the United States research on preventative health technologies finds that amidst the several challenges that exist in the market, vast opportunities are present for growth. The unique technology matrix included in the analysis evaluates the entire market landscape by health condition and level of medical professional involvement.  The research finds that although lack of incentives does slow the adoption process, government regulations and an exceeding burden on the economy are pushing healthcare professionals to reach new levels of service and technology innovation.

If you are interested in more information on this research, please email Britni Myers , Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

Due to a shortage of reimbursements available for the use of preventative technologies, many physicians and patients are hesitant to implement such systems, especially when they are uncertain about the cost-effectiveness. While i
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region
2. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
3. Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift from Traditional Mass-Media Platforms towards Personalization via Online and Social Media
4. ResearchMoz.US: Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift From Traditional Mass-Media Platforms Towards Personalization via Online and Social Media- Market Research Report
5. ASCO Impact Report From Encuity Research Indicates Oncologists Are Likely to Shift Patient Treatment Plans
6. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
7. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
8. Apollo Hospitals to Establish the First Proton Therapy Center for Cancer Treatment to Serve Over 3.5 Billion People
9. Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
10. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
11. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Company expands reach of ... big data, aerospace and defense, medical, and industrial, ... engineering R&D services company, today announced professional services ... for aerospace and defense , medical ... industrial , and visual computing applications. ...
(Date:7/29/2014)... Israel , July 30, 2014  Immune ... Stockholm : "IMNP."; "Immune" or "the ... of patients for a Phase II proof of concept ... in the treatment of moderate to severe bullous pemphigoid. ... receive two bertilimumab infusions, at a dose of 10 ...
(Date:7/29/2014)... -- Amgen (NASDAQ: AMGN ) today announced ... results include: , Total revenues increased 11 percent ... driven by strong performance across the portfolio, particularly Enbrel ... (denosumab) and XGEVA ® (denosumab). , ... higher revenues and a significant increase in the profitability ...
Breaking Medicine Technology:eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
(Date:7/30/2014)... July 30, 2014 The family of ... has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) ... Bernstein Liebhard LLP reports. According to the complaint, which ... of Vermont on July 25th, the decedent had been ... an irreversible brain bleed that ultimately led to his ...
(Date:7/30/2014)... 30, 2014 Visitors to our region ... $8,500 to ensure its protection. Bob Kiesendahl, one of ... to the Delaware Highlands Conservancy for donations collected through ... $2-per-stay donations add up fast, as visitors welcome the ... Delaware River Region. , The Kiesendahl family has owned ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- Some obese people ... the reward centers in their brains when they see ... how this mutation triggers feelings of pleasure and gratification ... help improve strategies designed to prevent overeating, the scientists ... obese. Obesity is typically caused by a combination ...
(Date:7/30/2014)... 2014 DRE Medical — a leading ... launch of its Medical Trade Shows & Conventions ... professionals and equipment vendors. , The calendar is a ... the United States and around the world. Hundreds of ... number is always growing. , Information listed on each ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people ... published this week in the peer-reviewed journal Quality of Life Research , a UCLA team led by Dr. Brennan Spiegel interviewed ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Gene Mutation May Make Food More Tempting 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3
... higher odds of heart attack, death, study found , , MONDAY, ... younger heart attack patients more prone to another heart attack, ... drug Plavix, researchers report. , The study is published in ... , Plavix plus low-dose aspirin are often used to prevent ...
... Experimental approach seemed to protect the animals from smoke,s ... News) -- In experiments in mice, scientists have shown ... the respiratory damage caused by cigarettes. , The finding ... disease (COPD) -- a chronic progressive lung disease involving ...
... Highway Traffic Safety Administration (NHTSA) revealed that an estimated ... will be on the roads this holiday season. In ... that involved a drunk driver from Thanksgiving through New ... the University of Georgia found that the most important ...
... Department of Energy,s (DOE) Brookhaven National Laboratory have determined ... neurotoxin a deadly toxin produced by certain bacteria ... in cosmetic and therapeutic applications such as reducing wrinkles ... online December 22, 2008, by the Journal of ...
... The Women,s Heart Health Initiative at the Cardiovascular Research ... fellowship dedicated to gender-specific research that will improve the ... The announcement will take place during a February luncheon ... unique challenges to successful diagnosis and treatment of heart ...
... Medicine (BUSM) have determined the optimal dose-management strategy to ... outcomes. Results of the study appear online in the ... and Haemostasis . , Warfarin is highly effective ... conditions. Numerous studies have focused on the underutilization ...
Cached Medicine News:Health News:Gene Ups Risk for Those on Blood-Thinner Plavix 2Health News:Gene Ups Risk for Those on Blood-Thinner Plavix 3Health News:Drug Shields Mice From Emphysema 2Health News:MU professor recommends changing drivers' perceptions of law enforcement to deter drunk driving 2Health News:Scientists reveal structure of new botulism nerve toxin subtype 2Health News:Scientists reveal structure of new botulism nerve toxin subtype 3Health News:Study shows optimal dose management of warfarin improves anticoagulation control 2
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: